Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metastatic Castration-resistant Prostate Cancer × Selegiline × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

testosterone 17 beta-cypionate 2 enzalutamide 2 darolutamide 2 Docetaxel 2 sipuleucel-T 1 pamiparib 1 olaparib 1 lactitol 1 fluciclovine F-18 1 enfortumab vedotin 1 cabazitaxel 1 avelumab 1 abiraterone 1 Standard of Care 1 Selegiline 1 Pluvicto 1 PSMA-617 1 Gonadotropin-Releasing Hormone 1 Bortezomib 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04586543 2020-10-14

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

University of Pecs

Phase 2 Unknown

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡